Vonaprument

N/A

Report date: 2025/07/25 15:00:05

Base Information

Drug NameVonaprument

Drug Alias NameANX-007ANX007

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionComplement C1q subcomponent inhibitors

TargetsComplement C1q subcomponent

Therapy Area/IndicationsGeographic AtrophyGlaucoma, Open-Angle

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaCanadaUnited States +[14]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAnnexon Inc

China Registration ClassN/A

Develop Information

Active CompaniesAnnexon Inc

Inactive CompaniesN/A

Active IndicationsGeographic Atrophy

Inactive IndicationsGlaucoma, Open-Angle

Other Information

ATC CodeN/A